Myelin oligodendrocyte glycoprotein antibody-associated disease – Diagnostics – Overview of Information and Clinical Research

Understanding how Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) is diagnosed involves a careful combination of clinical observation, specialized blood testing, and advanced imaging techniques—all working together to distinguish this rare condition from similar neurological disorders and guide appropriate treatment decisions.

Introduction: Who Should Seek Diagnostic Testing

If you or someone in your family experiences sudden vision problems, especially if accompanied by eye pain, or develops unexplained muscle weakness, numbness, or confusion, it may be time to consult a healthcare professional about possible neurological inflammation—swelling that affects the brain, spinal cord, or nerves that connect your eyes to your brain. MOGAD is a condition where the body’s immune system mistakenly attacks a protein called myelin oligodendrocyte glycoprotein, or MOG for short, which sits on the protective covering around nerves in your central nervous system. When this covering is damaged, the messages your brain sends throughout your body can be slowed down or blocked entirely.^[1]

Seeking diagnostics is especially important when symptoms appear suddenly and worsen over days. Children who develop confusion, unsteady walking, or behavioral changes after a recent illness should be evaluated promptly, as these may signal inflammation in the brain and spinal cord. Adults experiencing severe vision loss in one or both eyes, or weakness and numbness in the arms or legs, should also seek medical attention without delay. Early diagnosis can make a significant difference in how quickly and effectively treatment can be started, which in turn affects how well someone recovers from an attack.^[2]

It’s worth noting that MOGAD symptoms can sometimes be confused with other conditions such as multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD). These diseases share some overlapping features, but they are distinct conditions requiring different approaches to treatment. Because of this overlap, accurate diagnosis through specialized testing is essential to ensure that patients receive the right care and avoid treatments that may not be helpful or could even be harmful for their specific condition.^[9]

⚠️ Important

MOGAD often develops shortly after a viral infection or, less commonly, after vaccination. If you or your child develops neurological symptoms within days or weeks of being sick, this connection can be an important clue for your healthcare provider during the diagnostic process.

Diagnostic Methods for Identifying MOGAD

Diagnosing MOGAD typically involves two critical elements that must both be confirmed: first, that symptoms were caused by a typical attack pattern such as inflammation of the optic nerve, spinal cord, or brain; and second, that MOG antibodies are present in the blood or spinal fluid. Healthcare professionals use a combination of approaches to piece together the full diagnostic picture.^[9]

Clinical Evaluation and Physical Examination

The diagnostic journey begins with a thorough review of your symptoms and medical history. Your doctor will ask detailed questions about when symptoms started, how quickly they developed, and whether you recently had an infection or vaccination. A physical examination follows, often including a neurological exam where the doctor tests your vision, muscle strength, reflexes, coordination, and sensation in different parts of your body. This helps identify which areas of the nervous system may be affected by inflammation.^[2]

In children, doctors pay particular attention to recent behavioral changes, difficulty walking, or complaints of headaches that could actually be eye pain from optic neuritis—inflammation of the optic nerve. Young children may not always be able to describe their symptoms clearly, so careful observation by parents and healthcare providers becomes especially important.^[1]

MOG Antibody Blood Testing

The cornerstone of MOGAD diagnosis is detecting MOG antibodies in the blood. The most reliable method for this is called a cell-based assay, which is considered the gold standard for MOG antibody testing. In this test, laboratory technicians examine blood samples to see if antibodies attach to cells that have MOG protein on their surface. This approach is highly specific and sensitive, meaning it’s very good at correctly identifying people who have MOGAD.^[9]

However, interpreting MOG antibody tests requires caution and expertise. There is a possibility of false positives—results that suggest MOG antibodies are present when they actually aren’t. This is particularly likely when symptoms don’t match typical MOGAD patterns or when they look more like multiple sclerosis. For this reason, doctors must carefully consider the complete clinical picture rather than relying on test results alone.^[9]

It’s also important to understand that MOG antibodies may decrease over time and might not be detectable during periods when symptoms have gone away (called remission). This is especially true for children whose first presentation involves inflammation of both the brain and spinal cord. In some cases, antibodies may not be detectable very early in the disease process, so timing of the blood test matters.^[13]

Spinal Tap (Lumbar Puncture)

A spinal tap, also called a lumbar puncture, is a procedure where a small sample of cerebrospinal fluid—the liquid that surrounds your brain and spinal cord—is collected for testing. During this procedure, a needle is carefully inserted into the lower back to withdraw a small amount of fluid. The sample is then analyzed in a laboratory to look for signs of inflammation, such as an elevated count of white blood cells, which are immune cells that increase when the body is fighting what it perceives as a threat.^[9]

The spinal tap can also check for specific proteins called oligoclonal bands. These bands are more commonly found in people with multiple sclerosis rather than MOGAD. Their absence can help doctors distinguish between these two conditions, which is valuable information when symptoms could fit either diagnosis. Additionally, if blood test results for MOG antibodies are unclear or borderline, testing the cerebrospinal fluid for these antibodies can provide additional diagnostic clarity.^[9]

Magnetic Resonance Imaging (MRI)

MRI scans are powerful imaging tools that use magnets and radio waves to create detailed pictures of the brain, spinal cord, and optic nerves. These images can reveal areas of inflammation, called lesions, which appear as irregular spots or patches. The location, size, and appearance of these lesions provide important clues about whether someone has MOGAD or a different neurological condition.^[9]

In MOGAD, brain lesions often have a distinctive “fluffy” or “cloudy” appearance on MRI, meaning their edges are not sharply defined. These lesions typically involve both sides of the brain and often affect the white matter of the outer brain layer (cortex) as well as deeper structures. When the optic nerves are involved, MRI usually shows swelling affecting a long portion of the nerve, particularly the part closer to the eyeballs. In many cases, both optic nerves are affected during the first attack.^[3]

For spinal cord inflammation, MRI may reveal lesions that extend across multiple segments of the spine. The pattern and distribution of these lesions help doctors differentiate MOGAD from similar conditions. Specialized neuroradiologists—doctors who focus on interpreting images of the nervous system—examine these scans carefully to identify features characteristic of MOGAD.^[3]

Eye Examination and Optical Coherence Tomography

When vision problems are present, a comprehensive eye examination becomes part of the diagnostic workup. Doctors may perform a test called optical coherence tomography (OCT), which uses light waves to take detailed cross-sectional pictures of the retina—the light-sensitive tissue at the back of your eye—and the optic nerve. This test can detect swelling or damage to these structures that might not be visible during a regular eye exam.^[9]

During an examination with an ophthalmoscope (an instrument that allows doctors to look inside the eye), doctors may observe disc edema, which is swelling of the optic nerve where it enters the eye. In severe cases of MOGAD-related optic neuritis, there may even be small hemorrhages (bleeding) around the optic nerve head. These findings, combined with other test results, strengthen the diagnostic picture.^[6]

⚠️ Important

Because MOGAD can look similar to other neurological conditions, getting an accurate diagnosis often requires seeing specialists who have experience with rare neuroimmune disorders. Centers with expertise in these conditions are better equipped to interpret complex test results and distinguish MOGAD from similar diseases.

Diagnostic Testing for Clinical Trial Enrollment

When patients with MOGAD consider participating in clinical trials—research studies testing new treatments—they must undergo additional testing to determine if they meet the specific requirements for enrollment. These studies are carefully designed with strict criteria to ensure patient safety and to test treatments on the most appropriate population.^[4]

Confirmation of MOG Antibody Status

Clinical trials for MOGAD typically require confirmed presence of MOG antibodies using the cell-based assay method. This is because researchers want to study patients who definitively have MOGAD rather than similar conditions. Some trials may specify a minimum antibody level or titer, which is a measurement of how much antibody is present in the blood. Patients whose antibody levels have dropped below detectable limits during remission may not qualify for certain trials, while others may accept participants with a documented history of positive antibody testing.^[4]

Disease Activity and Attack History

Many clinical trials focus on preventing future attacks in people with relapsing MOGAD—the form where symptoms come and go with multiple episodes over time. To participate in these studies, patients often need to demonstrate evidence of disease activity, such as having experienced a certain number of attacks within a specified timeframe. Trial coordinators review medical records documenting previous attacks, including emergency room visits, hospitalizations, and treatment with high-dose steroids or other medications used during acute episodes.^[4]

Conversely, some research studies may focus on people who have experienced only one attack (monophasic MOGAD) to understand factors that determine whether someone will have additional episodes. These studies have different enrollment criteria based on time since the initial attack and absence of subsequent relapses.^[13]

Baseline MRI and Neurological Function

Before enrolling in a clinical trial, participants typically undergo baseline MRI scans of the brain, spinal cord, and sometimes optic nerves. These images establish a starting point against which future scans can be compared to measure whether an experimental treatment is preventing new lesions or reducing existing inflammation. Researchers document the number, size, and location of lesions at the beginning of the study.^[3]

Similarly, baseline assessments of neurological function are performed, which may include standardized tests of vision (such as visual acuity charts and color vision tests), muscle strength, walking ability, sensation, and cognitive function. These measurements help researchers track whether participants improve, stabilize, or worsen during the trial.^[9]

Exclusion of Other Conditions

Clinical trials have lists of conditions that would exclude someone from participating. For MOGAD trials, this often includes testing negative for antibodies associated with other similar diseases, particularly aquaporin-4 antibodies that are found in neuromyelitis optica spectrum disorder. Blood tests, spinal fluid analysis, and careful review of medical history help ensure that participants truly have MOGAD and not a different condition that might respond differently to the treatment being studied.^[4]

Safety Laboratory Tests

Before starting any experimental treatment in a clinical trial, participants undergo comprehensive laboratory testing to ensure they can safely receive the therapy. This typically includes blood tests to check liver function, kidney function, blood cell counts, and immune system status. These baseline measurements help researchers monitor for potential side effects during the trial. Some trials may exclude people with certain underlying medical conditions or those taking medications that could interact with the experimental treatment.^[4]

Ongoing Monitoring Requirements

Throughout a clinical trial, participants undergo regular follow-up testing, which may be more frequent and comprehensive than standard clinical care. This often includes repeated MRI scans at scheduled intervals (such as every few months), regular blood tests to monitor MOG antibody levels and safety parameters, and periodic neurological examinations to detect any changes in function. While these requirements represent a significant time commitment, the close monitoring can provide early detection of disease activity or treatment side effects.^[4]

Patients interested in clinical trial participation should discuss with their healthcare providers whether they might qualify for available studies. Organizations focused on rare neuroimmune disorders often maintain registries and provide information about ongoing research opportunities.^[13]

Prognosis and Survival Rate

Prognosis

The outlook for people with MOGAD varies considerably depending on several factors, including whether the disease follows a monophasic (single attack) or relapsing (multiple attacks) pattern. About 40 to 50 percent of individuals with MOGAD experience only one attack in their lifetime, particularly young children whose first presentation involves inflammation of both the brain and spinal cord. In these cases, recovery with appropriate treatment is often very good, and many people return to their normal activities without long-term disability.^[13]

For those who experience relapsing disease, the prognosis remains relatively favorable compared to similar conditions like neuromyelitis optica spectrum disorder. The level of disability after MOGAD attacks is usually less severe, and recovery with appropriate therapies tends to be better. Interestingly, individuals who have multiple attacks often find that later episodes are less severe than earlier ones. However, repeated attacks do carry a risk of accumulating disability over time.^[13]

Certain factors appear to influence long-term outcomes. Young children, especially those presenting with acute disseminated encephalomyelitis (inflammation of the brain and spinal cord), are more likely to have a single episode and good recovery. Older children and adults, particularly those whose first symptom is optic neuritis (inflammation of the optic nerve), have a higher likelihood of experiencing additional attacks. People whose initial attack involved spinal cord inflammation may face a higher chance of long-term disability, particularly if the attack was severe or treatment was delayed.^[13]

Some individuals continue to test positive for MOG antibodies over time, and studies suggest these people may have a higher chance of experiencing relapses compared to those whose antibodies disappear. This is why ongoing monitoring of antibody levels can provide valuable information about disease activity and help guide treatment decisions. However, the relationship between antibody levels and disease course is complex and varies from person to person.^[13]

Permanent complications from MOGAD can include blindness in one or both eyes, bladder or bowel dysfunction, paralysis of the arms or legs, chronic pain, chronic fatigue, and cognitive difficulties with learning, memory, and thinking. The risk of these complications increases with the severity and frequency of attacks, underscoring the importance of prompt treatment during acute episodes and consideration of preventive therapies for those with relapsing disease.^[2]

Survival Rate

MOGAD is not typically considered a life-threatening condition, and information specifically about survival rates is not extensively documented in the medical literature. Unlike some other serious neurological conditions, MOGAD does not appear to significantly reduce life expectancy for most patients. The primary concern with MOGAD is not mortality but rather the potential for disability and impact on quality of life from accumulated damage to the nervous system over time.^[1]

However, severe attacks affecting critical areas of the brain or brainstem could potentially be life-threatening, particularly if they affect the parts of the nervous system that control breathing or heart function. Prompt recognition of severe symptoms and immediate medical treatment are essential in such rare circumstances. The vast majority of people with MOGAD, when properly diagnosed and treated, can expect to live a normal lifespan, though they may need to manage ongoing symptoms and take preventive medications to reduce the risk of future attacks.^[2]

#1 Clinical Trials Search in Europe